Breast carcinoma
breast carcinoma histology pathology

Bright-field light microscopy of an H&E-stained breast tissue section. The image captures parenchymal breast tissue with a high-grade, basal-like carcinoma component displaying geographic necrosis within tumor nests. Tumor cells are pleomorphic with hyperchromatic nuclei, conspicuous nucleoli, and scant cytoplasm arranged in solid sheets and cords; mitotic activity is brisk, contributing to the aggressive histology. The surrounding stroma shows infiltrating tumor cells at the margins, with limited luminal differentiation and a basal-type immunophenotype suggested by cytokeratin-positive basaloid cells (not shown here). This basal-like phenotype is characteristic of triple-negative breast cancers, which often lack estrogen receptor, progesterone receptor, and HER2 overexpression, and tend to behave aggressively with higher grade and poorer prognosis. The image exemplifies features used to distinguish basal-like breast carcinoma from luminal subtypes, such as geography-like necrosis and high mitotic index (>40 mitoses per 10 high-power fields) as described in published pathology resources. Knowledge of this histology supports diagnostic categorization, prognostic assessment, and therapeutic planning, including eligibility for neoadjuvant chemotherapy and enrollment in subtype-specific studies. In educational contexts, this image serves as a reference for recognizing basal-like morphology, comparing with serous ovarian tumor mutational patterns, and reinforcing the link between histology and molecular subtype stratification in breast cancer clinical practice.

Gross pathology photograph of a human breast tissue specimen displaying a large, multifocal, high-grade invasive ductal carcinoma with extensive involvement of the overlying skin. Modality: gross pathology imaging; technique: en-face macroscopic view with scale ruler included, color in natural balance. The breast parenchyma shows multiple whitish, firm nodules interspersed within adipose tissue, with irregular, infiltrative margins. The skin over the lesion is visibly involved, exhibiting erythema and induration consistent with dermal invasion by tumor. No formal staining or contrast is applied in this gross photograph; histology would be required to confirm lymphovascular invasion. The lesion spans a substantial portion of the specimen and demonstrates heterogeneity in consistency and color, ranging from pale yellow to whitish fibrous areas. Clinically, this pattern corresponds to locally advanced breast cancer with cutaneous involvement, which has implications for staging (T4-like features), prognosis, and surgical planning (mastectomy versus breast-conserving approaches). This image serves educational purposes for trainees in pathology, oncology, breast surgery, and radiology, illustrating how invasive ductal carcinoma can present with extensive skin invasion on gross examination. Potential differential considerations include inflammatory breast carcinoma and other high-grade ductal neoplasms; correlate with imaging and biopsy for definitive diagnosis.

Imaging modality: Light microscopy using bright-field, Hematoxylin and Eosin (H&E) staining of a breast tissue section. Precise anatomical location: Mammary gland parenchyma, intratumoral mass within breast tissue; subtype: medullary carcinoma of the breast. Visual features: diffuse, sheet-like growth with broad cellular nests and anastomosing trabeculae; tumor cells with high-grade, pleomorphic nuclei and abundant eosinophilic cytoplasm; indistinct cytoplasmic borders producing a syncytial cytomorphology; lack of glandular differentiation and absence of an intraductal component. Microenvironment: prominent lymphoid and plasmacytic infiltrate both within and surrounding the tumor, creating a rich inflammatory milieu. Pathological interpretation: histology consistent with medullary carcinoma; margins and invasion assessed by surrounding tissue; phenotype often triple-negative with basal-like features; high cellularity contrasted by dense lymphoid infiltration. Diagnostic significance: recognition of characteristic syncytial architecture and inflammatory infiltrate supports diagnosis; prognosis is relatively favorable for medullary-type breast carcinomas compared with other triple-negative basaloid cancers; important for differential diagnosis with inflammatory/ductal carcinomas. Clinical relevance: guides treatment planning including surgery and systemic therapy; immunohistochemistry (ER/PR/HER2) and molecular profiling may clarify receptor status; imaging-pathology correlation essential for accurate classification and prognosis. In educational contexts, this image demonstrates classic medullary histology, aiding differential diagnosis awareness, grading schemes, and teaching concepts of tumor-infiltrating lymphocytes and syncytial morphology in breast pathology for students and clinicians.

Imaging modality and technique: Light microscopy of a hematoxylin-eosin stained breast tissue section. Anatomical location: breast parenchyma; histology reveals a metaplastic carcinoma dominated by undifferentiated spindle cells arranged in fascicles with marked pleomorphism, high mitotic activity, and areas of chondrosarcomatous differentiation forming dense cartilaginous matrix. Rare foci show adenosquamous differentiation with epithelial glandular elements and squamous features embedded in the spindle stroma. The lesion demonstrates biphasic morphology comprising epithelial and mesenchymal components, characteristic of metaplastic breast carcinoma. Notable features include heterogeneous cellularity, loss of cohesion in spindle cells, abundant eosinophilic cartilaginous matrix, and invasion into surrounding breast stroma. Differential diagnosis includes primary breast sarcoma and ossifying/chondroid metaplasia vs metastatic disease. When such tumors metastasize, epithelial elements may predominate or mesenchymal elements may prevail; metastases to bone can resemble primary bone tumors, complicating diagnosis. Clinically, this entity is associated with aggressive behavior, triple-negative phenotype, and poor prognosis, often requiring comprehensive immunohistochemical profiling to identify epithelial markers (cytokeratins) within the sarcomatous areas. This image is relevant for educational purposes in surgical pathology, breast oncology, and histopathology training, illustrating the spectrum of heterologous differentiation in metaplastic breast carcinoma and its diagnostic challenges in distinguishing from primary bone tumors for pathology teaching purposes.
"breast cancer"[MeSH Terms] AND "treatment"[MeSH Terms]
| Category | Factor | Relative Risk |
|---|---|---|
| Modifiable | Obesity (BMI >30), postmenopausal | RR 1.29 |
| Nulliparity / first pregnancy >35 yr | Increased | |
| HRT use >10 years | RR 1.2 | |
| Alcohol (>4 drinks/day) | RR 1.46 | |
| Radiation exposure | RR 6 | |
| Tobacco (≥25 cig/day) | RR 1.14 | |
| Non-modifiable | Increasing age | Strong |
| Female sex | 100:1 (F:M) | |
| BRCA1/BRCA2 germline mutations | ~12% of all breast cancers | |
| Prior DCIS or LCIS | High | |
| Family history (1st degree) | RR 2-4 | |
| Early menarche / late menopause | Increased estrogenic exposure | |
| Dense breast tissue | Increased |

| Type | Frequency |
|---|---|
| Invasive ductal carcinoma - No Special Type (NST) | ~75-80% |
| Invasive lobular carcinoma | 10-15% |
| Medullary carcinoma (now reclassified as NST with medullary pattern) | ~4% |
| Mucinous (colloid) carcinoma | ~2% |
| Papillary carcinoma | ~2% |
| Tubular carcinoma | ~2% |
| Paget's disease of the nipple | Rare |
| Rare types (adenoid cystic, squamous, metaplastic, apocrine) | <1% |
| Subtype | ER/PR | HER2 | Frequency | Characteristics |
|---|---|---|---|---|
| Luminal (ER+/HER2-) - low proliferation | + | - | 40-55% | Best prognosis; hormone-sensitive |
| Luminal (ER+/HER2-) - high proliferation | + | - | ~10% | Intermediate; Ki-67 high |
| HER2-positive | +/- | + | ~20% | Aggressive; responds to anti-HER2 therapy |
| Triple-Negative (TNBC) | - | - | ~15% | Aggressive; no targeted therapy; basal-like overlap |
| Subtype | Frequency | Key Features |
|---|---|---|
| Luminal A | 35-45% | Low grade, ER+, low Ki-67, best prognosis |
| Luminal B | 20-25% | Higher grade, ER+, higher Ki-67, worse prognosis than Luminal A |
| HER2-enriched | 5-10% | HER2 amplified, ER-, aggressive |
| Basal-like | 15-20% | ER-/PR-/HER2-, BRCA1-associated, high grade, TNBC overlap |
| Normal-like | Rare | Good prognosis |
| Claudin-low | Rare | Stem cell-like, poor prognosis |


| Stage | Tumor (T) | Nodes (N) | Metastasis (M) | 10-yr Survival |
|---|---|---|---|---|
| 0 | DCIS | No metastases | Absent | 97% |
| I | Invasive ≤2 cm | None or micrometastases | Absent | 87% |
| II | >2 cm or >2-5 cm | 1-3 positive LNs or 0-3 | Absent | 65% |
| III | >5 cm / any / skin/chest wall / inflammatory | Variable | Absent | 40% |
| IV | Any | Any | Present | ~5% |
| Biomarker | Role |
|---|---|
| ER/PR | Predicts response to hormonal therapy (tamoxifen, aromatase inhibitors) |
| HER2 | Predicts response to trastuzumab, pertuzumab, T-DM1, lapatinib |
| Ki-67 | Proliferation index; distinguishes Luminal A from B |
| BRCA1/2 | Predicts PARP inhibitor response (olaparib, talazoparib) |
| PIK3CA mutation | Predicts response to PI3K inhibitors (alpelisib) in ER+/HER2- |
| PD-L1 | Predicts benefit from immune checkpoint inhibitors in TNBC |
| Multigene assays (Oncotype DX, MammaPrint) | Guide chemotherapy decisions in early-stage ER+/HER2- |
| Circulating tumor DNA (ctDNA) | Emerging: detects emerging actionable mutations |

| Subtype | Treatment |
|---|---|
| ER+/HER2- | Endocrine therapy (tamoxifen premenopausal; aromatase inhibitors postmenopausal) ± CDK4/6 inhibitors; chemotherapy if high-risk |
| HER2+ | Anti-HER2 therapy (trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan) + chemotherapy |
| Triple-Negative | Chemotherapy (anthracyclines + taxanes); immunotherapy (pembrolizumab for PD-L1+); PARP inhibitors if BRCA mutated |
| Metastatic (all types) | Palliative systemic therapy; bisphosphonates/denosumab for bone metastases |